Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

01-10-2018 | Original Paper

Neural substrate of unrelenting negative symptoms in schizophrenia: a longitudinal resting-state fMRI study

Authors: Mingli Li, Wei Deng, Tushar Das, Yinfei Li, Liansheng Zhao, Xiaohong Ma, Yingcheng Wang, Hua Yu, Xiaojing Li, Ya-jing Meng, Qiang Wang, Lena Palaniyappan, Tao Li

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 7/2018

Abstract

Developing a mechanistic insight into the specific brain processes that underpin improvement in negative symptoms can help us design novel chemical and physical treatments against these unrelenting symptoms. The aim of the present study is to explore the longitudinal changes in the brain’s regional functional efficiency that accompany improvement in negative symptoms seen in first-episode patients with schizophrenia when treated with antipsychotic for 1 year. Forty-seven first-episode patients with schizophrenia were scanned at a drug-naive baseline state and followed up for 1 year to identify negative symptom responders (Rn) and non-responders (NRn). Fractional amplitude of low-frequency fluctuations (fALFF) and Granger analysis of effective connectivity (EC) were used to examine the different patterns of regional function and connectivity between Rn and NRn during the 1 year follow-up. Increase of fALFF in the left superior temporal gyrus (STG) and increase of EC from the left STG to the dorsolateral prefrontal cortex (DLPFC) was found in Rn compared to NRn. We further validated that the identified changes in fALFF/EC of STG occur specifically in relation to negative symptoms only (i.e., not pseudo-specific in relation to positive, extrapyramidal or depressive symptoms), and occur irrespective of arbitrary clinical categorization of treatment response. An increase in fALFF in the precuneus and the inferior parietal lobule, and a decrease in EC from the left STG to the occipital cortex, were also found at the 1 year follow-up irrespective of improvement in negative symptoms. Interventions that improve the functional efficiency of left STG and its prefrontal connectivity may show efficacy in alleviating negative symptoms in first-episode schizophrenia.

Available only for authorised users

Bleuler E (1911) Dementia praecox oder Gruppe der Schizophrenien. Handbuch der psychiatrie

Fervaha G, Agid O, Foussias G, Siddiqui I, Takeuchi H, Remington G (2016) Neurocognitive impairment in the deficit subtype of schizophrenia. Eur Arch Psychiatry Clin Neurosci 266(5):397–407. https://doi.org/10.1007/s00406-015-0629-6 CrossRefPubMed

Herbener ES, Harrow M (2004) Are negative symptoms associated with functioning deficits in both schizophrenia and nonschizophrenia patients? A 10-year longitudinal analysis. Schizophr Bull 30(4):813–825. https://doi.org/10.1093/oxfordjournals.schbul.a007134 CrossRefPubMed

Mancevski B, Keilp J, Kurzon M, Berman RM, Ortakov V, Harkavy-Friedman J, Rosoklija G, Dwork AJ (2007) Lifelong course of positive and negative symptoms in chronically institutionalized patients with schizophrenia. Psychopathology 40(2):83–92. https://doi.org/10.1159/000098488 CrossRefPubMed

Gee B, Hodgekins J, Fowler D, Marshall M, Everard L, Lester H, Jones PB, Amos T, Singh SP, Sharma V, Freemantle N, Birchwood M (2016) The course of negative symptom in first episode psychosis and the relationship with social recovery. Schizophr Res 174(1–3):165–171. https://doi.org/10.1016/j.schres.2016.04.017 CrossRefPubMed

Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, McGuire P (2015) Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull 41(4):892–899. https://doi.org/10.1093/schbul/sbu170 CrossRefPubMed

Hovington CL, Lepage M (2012) Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia. Expert Rev Neurother 12(1):53–69. https://doi.org/10.1586/ern.11.173 CrossRefPubMed

Millan MJ, Fone K, Steckler T, Horan WP (2014) Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 24(5):645–692. https://doi.org/10.1016/j.euroneuro.2014.03.008 CrossRef

Shin JE, Choi SH, Lee H, Shin YS, Jang DP, Kim JJ (2015) Involvement of the dorsolateral prefrontal cortex and superior temporal sulcus in impaired social perception in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 58:81–88. https://doi.org/10.1016/j.pnpbp.2014.12.006 CrossRefPubMed

10.

Buchy L, Ad-Dab’bagh Y, Lepage C, Malla A, Joober R, Evans A, Lepage M (2012) Symptom attribution in first episode psychosis: a cortical thickness study. Psychiatry Res 203(1):6–13. https://doi.org/10.1016/j.pscychresns.2011.09.009 CrossRefPubMed

11.

Sun J, Maller JJ, Guo L, Fitzgerald PB (2009) Superior temporal gyrus volume change in schizophrenia: a review on region of interest volumetric studies. Brain Res Rev 61(1):14–32. https://doi.org/10.1016/j.brainresrev.2009.03.004 CrossRefPubMed

12.

Vita A, De Peri L, Deste G, Sacchetti E (2012) Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. Transl Psychiatry 2:e190. https://doi.org/10.1038/tp.2012.116 CrossRefPubMedPubMedCentral

13.

Hasan A, Wobrock T, Guse B, Langguth B, Landgrebe M, Eichhammer P, Frank E, Cordes J, Wolwer W, Musso F, Winterer G, Gaebel W, Hajak G, Ohmann C, Verde PE, Rietschel M, Ahmed R, Honer WG, Dechent P, Malchow B, Castro MFU, Dwyer D, Cabral C, Kreuzer PM, Poeppl TB, Schneider-Axmann T, Falkai P, Koutsouleris N (2017) Structural brain changes are associated with response of negative symptoms to prefrontal repetitive transcranial magnetic stimulation in patients with schizophrenia. Mol Psychiatry 22(6):857–864. https://doi.org/10.1038/mp.2016.161 CrossRefPubMed

14.

Zou QH, Zhu CZ, Yang Y, Zuo XN, Long XY, Cao QJ, Wang YF, Zang YF (2008) An improved approach to detection of amplitude of low-frequency fluctuation (ALFF) for resting-state fMRI: fractional ALFF. J Neurosci Methods 172(1):137–141. https://doi.org/10.1016/j.jneumeth.2008.04.012 CrossRefPubMedPubMedCentral

15.

Eichler M (2005) A graphical approach for evaluating effective connectivity in neural systems. Philos Trans R Soc Lond B Biol Sci 360(1457):953–967. https://doi.org/10.1098/rstb.2005.1641 CrossRefPubMedPubMedCentral

16.

Annett M (1970) A classification of hand preference by association analysis. Br J Psychol 61(3):303–321. https://doi.org/10.1111/j.2044-8295.1970.tb01248.x CrossRefPubMed

17.

Kay SR, Flszbein A, Opfer LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276. https://doi.org/10.1093/schbul/13.2.261 CrossRefPubMed

18.

Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R (2000) Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 101(4):323–329. https://doi.org/10.1034/j.1600-0447.2000.101004323.x PubMedCrossRef

19.

Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr (1989) The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 30(2):119–123. https://doi.org/10.1016/0165-1781(89)90153-4 CrossRefPubMed

20.

van der Gaag M, Hoffman T, Remijsen M, Hijman R, de Haan L, van Meijel B, van Harten PN, Valmaggia L, De Hert M, Cuijpers A (2006) The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr Res 85(1):280–287. https://doi.org/10.1016/j.schres.2006.03.021 PubMedCrossRef

21.

Levine SZ, Rabinowitz J, Engel R, Etschel E, Leucht S (2008) Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res 98(1–3):318–322. https://doi.org/10.1016/j.schres.2007.09.006 CrossRefPubMed

22.

Carbon M, Correll CU (2014) Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci 16(4):505–524PubMedPubMedCentral

23.

Maria Atkins AB, Bottomley Clare, Riccio Massimo (1997) Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications. Psychiatr Bull 21:224–226. https://doi.org/10.1192/pb.21.4.224 CrossRef

24.

Woods SW (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64(6):663–667. https://doi.org/10.4088/JCP.v64n0607 CrossRefPubMed

25.

Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11–19. https://doi.org/10.1111/j.1600-0447.1970.tb02066.x CrossRefPubMed

26.

Guy W (1976) ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs

27.

Yan C, Zang Y (2010) DPARSF: a MATLAB Toolbox for “Pipeline” data analysis of resting-state fMRI. Front Syst Neurosci 4:13. https://doi.org/10.3389/fnsys.2010.00013 CrossRef

28.

Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE (2012) Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage 59(3):2142–2154. https://doi.org/10.1016/j.neuroimage.2011.10.018 CrossRefPubMed

29.

Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME (2005) The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci USA 102(27):9673–9678. https://doi.org/10.1073/pnas.0504136102 CrossRefPubMed

30.

Fox MD, Zhang D, Snyder AZ, Raichle ME (2009) The global signal and observed anticorrelated resting state brain networks. J Neurophysiol 101(6):3270–3283. https://doi.org/10.1152/jn.90777.2008 CrossRefPubMedPubMedCentral

31.

Friston KJ, Williams S, Howard R, Frackowiak RS, Turner R (1996) Movement-related effects in fMRI time-series. Magn Reson Med 35(3):346–355. https://doi.org/10.1002/mrm.1910350312 CrossRefPubMed

32.

Biswal B, Zerrin Yetkin F, Haughton VM, Hyde JS (1995) Functional connectivity in the motor cortex of resting human brain using echo-planar mri. Magn Reson Med 34(4):537–541. https://doi.org/10.1002/mrm.1910340409 CrossRefPubMed

33.

Yan CG, Cheung B, Kelly C, Colcombe S, Craddock RC, Di Martino A, Li Q, Zuo XN, Castellanos FX, Milham MP (2013) A comprehensive assessment of regional variation in the impact of head micromovements on functional connectomics. Neuroimage 76:183–201. https://doi.org/10.1016/j.neuroimage.2013.03.004 CrossRefPubMedPubMedCentral

34.

Iwabuchi SJ, Peng D, Fang Y, Jiang K, Liddle EB, Liddle PF, Palaniyappan L (2014) Alterations in effective connectivity anchored on the insula in major depressive disorder. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 24(11):1784–1792. https://doi.org/10.1016/j.euroneuro.2014.08.005 CrossRef

35.

Palaniyappan L, Simmonite M, White TP, Liddle EB, Liddle PF (2013) Neural primacy of the salience processing system in schizophrenia. Neuron 79(4):814–828. https://doi.org/10.1016/j.neuron.2013.06.027 CrossRefPubMedPubMedCentral

36.

Lopez-Larson MP, Anderson JS, Ferguson MA, Yurgelun-Todd D (2011) Local brain connectivity and associations with gender and age. Dev Cognit Neurosci 1(2):187–197. https://doi.org/10.1016/j.dcn.2010.10.001 CrossRef

37.

Chumbley JR, Friston KJ (2009) False discovery rate revisited: FDR and topological inference using Gaussian random fields. Neuroimage 44(1):62–70. https://doi.org/10.1016/j.neuroimage.2008.05.021 CrossRefPubMed

38.

Kraguljac NV, White DM, Hadley N, Hadley JA, Ver Hoef L, Davis E, Lahti AC (2016) Aberrant hippocampal connectivity in unmedicated patients with schizophrenia and effects of antipsychotic medication: a longitudinal resting state functional MRI study. Schizophr Bull 42(4):1046–1055. https://doi.org/10.1093/schbul/sbv228 CrossRefPubMedPubMedCentral

39.

Hadley JA, Nenert R, Kraguljac NV, Bolding MS, White DM, Skidmore FM, Visscher KM, Lahti AC (2014) Ventral tegmental area/midbrain functional connectivity and response to antipsychotic medication in schizophrenia. Neuropsychopharmacology 39(4):1020–1030. https://doi.org/10.1038/npp.2013.305 CrossRefPubMed

40.

Paul S, Sharfman N (2016) Functional connectivity as a means to delineate differences between treatment-resistant and treatment-responsive schizophrenia. J Neurophysiol 116(2):229–231. https://doi.org/10.1152/jn.01127.2015 CrossRefPubMedPubMedCentral

41.

White TP, Wigton R, Joyce DW, Collier T, Fornito A, Shergill SS (2016) Dysfunctional striatal systems in treatment-resistant schizophrenia. Neuropsychopharmacology 41(5):1274–1285. https://doi.org/10.1038/npp.2015.277 CrossRefPubMed

42.

Sarpal DK, Argyelan M, Robinson DG, Szeszko PR, Karlsgodt KH, John M, Weissman N, Gallego JA, Kane JM, Lencz T, Malhotra AK (2016) Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment. Am J Psychiatry 173(1):69–77. https://doi.org/10.1176/appi.ajp.2015.14121571 CrossRefPubMed

43.

Guo W, Liu F, Chen J, Wu R, Li L, Zhang Z, Zhao J (2017) Olanzapine modulation of long- and short-range functional connectivity in the resting brain in a sample of patients with schizophrenia. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 27(1):48–58. https://doi.org/10.1016/j.euroneuro.2016.11.002 CrossRef

44.

Li P, Jing RX, Zhao RJ, Ding ZB, Shi L, Sun HQ, Lin X, Fan TT, Dong WT, Fan Y, Lu L (2017) Electroconvulsive therapy-induced brain functional connectivity predicts therapeutic efficacy in patients with schizophrenia: a multivariate pattern recognition study. NPJ schizophrenia 3:21. https://doi.org/10.1038/s41537-017-0023-7 CrossRefPubMedPubMedCentral

45.

Schmitt A, Hasan A, Gruber O, Falkai P (2011) Schizophrenia as a disorder of disconnectivity. Eur Arch Psychiatry Clin Neurosci 261(Suppl 2):S150–S154. https://doi.org/10.1007/s00406-011-0242-2 CrossRefPubMed

46.

Ganella EP, Bartholomeusz CF, Seguin C, Whittle S, Bousman C, Phassouliotis C, Everall I, Pantelis C, Zalesky A (2017) Functional brain networks in treatment-resistant schizophrenia. Schizophr Res 184:73–81. https://doi.org/10.1016/j.schres.2016.12.008 CrossRefPubMed

47.

Williams LM (2008) Voxel-based morphometry in schizophrenia: implications for neurodevelopmental connectivity models, cognition and affect. Expert Rev Neurother 8(7):1049–1065. https://doi.org/10.1586/14737175.8.7.1049 CrossRefPubMed

48.

Honea R, Crow TJ, Passingham D, Mackay CE (2005) Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am J Psychiatry 162(12):2233–2245. https://doi.org/10.1176/appi.ajp.162.12.2233 CrossRefPubMed

49.

Fischer BA, Keller WR, Arango C, Pearlson GD, McMahon RP, Meyer WA, Francis A, Kirkpatrick B, Carpenter WT, Buchanan RW (2012) Cortical structural abnormalities in deficit versus nondeficit schizophrenia. Schizophr Res 136(1–3):51–54. https://doi.org/10.1016/j.schres.2012.01.030 CrossRefPubMedPubMedCentral

50.

Huys QJ, Maia TV, Frank MJ (2016) Computational psychiatry as a bridge from neuroscience to clinical applications. Nat Neurosci 19(3):404–413. https://doi.org/10.1038/nn.4238 CrossRefPubMedPubMedCentral

51.

Zilbovicius M, Meresse I, Chabane N, Brunelle F, Samson Y, Boddaert N (2006) Autism, the superior temporal sulcus and social perception. Trends Neurosci 29(7):359–366. https://doi.org/10.1016/j.tins.2006.06.004 CrossRefPubMed

52.

Friston K, Brown HR, Siemerkus J, Stephan KE (2016) The dysconnection hypothesis (2016). Schizophr Res 176(2–3):83–94. https://doi.org/10.1016/j.schres.2016.07.014 CrossRefPubMedPubMedCentral

53.

Adolphs R (2003) Cognitive neuroscience of human social behaviour. Nat Rev Neurosci 4(3):165–178. https://doi.org/10.1038/nrn1056 CrossRefPubMed

54.

Savla GN, Vella L, Armstrong CC, Penn DL, Twamley EW (2013) Deficits in domains of social cognition in schizophrenia: a meta-analysis of the empirical evidence. Schizophr Bull 39(5):979–992. https://doi.org/10.1093/schbul/sbs080 CrossRefPubMed

55.

Healey KM, Bartholomeusz CF, Penn DL (2016) Deficits in social cognition in first episode psychosis: a review of the literature. Clin Psychol Rev 50:108–137. https://doi.org/10.1016/j.cpr.2016.10.001 CrossRefPubMed

56.

Ventura J, Wood RC, Hellemann GS (2013) Symptom domains and neurocognitive functioning can help differentiate social cognitive processes in schizophrenia: a meta-analysis. Schizophr Bull 39(1):102–111. https://doi.org/10.1093/schbul/sbr067 CrossRefPubMed

57.

Edwards J, Pattison PE, Jackson HJ, Wales RJ (2001) Facial affect and affective prosody recognition in first-episode schizophrenia. Schizophr Res 48(2–3):235–253CrossRefPubMed

58.

Vohs JL, Lysaker PH, Francis MM, Hamm J, Buck KD, Olesek K, Outcalt J, Dimaggio G, Leonhardt B, Liffick E, Mehdiyoun N, Breier A (2014) Metacognition, social cognition, and symptoms in patients with first episode and prolonged psychoses. Schizophr Res 153(1–3):54–59. https://doi.org/10.1016/j.schres.2014.01.012 CrossRefPubMed

59.

Lee SY, Bang M, Kim KR, Lee MK, Park JY, Song YY, Kang JI, Lee E, An SK (2015) Impaired facial emotion recognition in individuals at ultra-high risk for psychosis and with first-episode schizophrenia, and their associations with neurocognitive deficits and self-reported schizotypy. Schizophr Res 165(1):60–65. https://doi.org/10.1016/j.schres.2015.03.026 CrossRefPubMed

60.

Ventura J, Ered A, Gretchen-Doorly D, Subotnik KL, Horan WP, Hellemann GS, Nuechterlein KH (2015) Theory of mind in the early course of schizophrenia: stability, symptom and neurocognitive correlates, and relationship with functioning. Psychol Med 45(10):2031–2043. https://doi.org/10.1017/S0033291714003171 CrossRefPubMed

61.

Langdon R, Still M, Connors MH, Ward PB, Catts SV (2014) Theory of mind in early psychosis. Early Interv Psychiatry 8(3):286–290. https://doi.org/10.1111/eip.12072 CrossRefPubMed

62.

Mazza M, Pollice R, Pacitti F, Pino MC, Mariano M, Tripaldi S, Casacchia M, Roncone R (2012) New evidence in theory of mind deficits in subjects with chronic schizophrenia and first episode: correlation with symptoms, neurocognition and social function. Rivista di psichiatria 47(4):327–336. https://doi.org/10.1708/1139.12561 PubMedCrossRef

63.

Addington J, Saeedi H, Addington D (2006) Influence of social perception and social knowledge on cognitive and social functioning in early psychosis. Br J Psychiatry J Ment Sci 189:373–378. https://doi.org/10.1192/bjp.bp.105.021022 CrossRef

64.

Green MF, Bearden CE, Cannon TD, Fiske AP, Hellemann GS, Horan WP, Kee K, Kern RS, Lee J, Sergi MJ, Subotnik KL, Sugar CA, Ventura J, Yee CM, Nuechterlein KH (2012) Social cognition in schizophrenia, part 1: performance across phase of illness. Schizophr Bull 38(4):854–864. https://doi.org/10.1093/schbul/sbq171 CrossRefPubMed

65.

Cabral C, Kambeitz-Ilankovic L, Kambeitz J, Calhoun VD, Dwyer DB, von Saldern S, Urquijo MF, Falkai P, Koutsouleris N (2016) Classifying schizophrenia using multimodal multivariate pattern recognition analysis: evaluating the impact of individual clinical profiles on the neurodiagnostic performance. Schizophr Bull 42(Suppl 1):S110–S117. https://doi.org/10.1093/schbul/sbw053 CrossRefPubMedPubMedCentral

66.

Pettersson-Yeo W, Allen P, Benetti S, McGuire P, Mechelli A (2011) Dysconnectivity in schizophrenia: where are we now? Neurosci Biobehav Rev 35(5):1110–1124. https://doi.org/10.1016/j.neubiorev.2010.11.004 CrossRefPubMed

67.

Benetti S, Pettersson-Yeo W, Allen P, Catani M, Williams S, Barsaglini A, Kambeitz-Ilankovic LM, McGuire P, Mechelli A (2015) Auditory verbal hallucinations and brain dysconnectivity in the perisylvian language network: a multimodal investigation. Schizophr Bull 41(1):192–200. https://doi.org/10.1093/schbul/sbt172 CrossRefPubMed

68.

Thoma RJ, Hanlon FM, Moses SN, Ricker D, Huang M, Edgar C, Irwin J, Torres F, Weisend MP, Adler LE, Miller GA, Canive JM (2005) M50 sensory gating predicts negative symptoms in schizophrenia. Schizophr Res 73(2–3):311–318. https://doi.org/10.1016/j.schres.2004.07.001 CrossRefPubMed

69.

Kim DW, Shim M, Kim JI, Im CH, Lee SH (2014) Source activation of P300 correlates with negative symptom severity in patients with schizophrenia. Brain Topogr 27(2):307–317. https://doi.org/10.1007/s10548-013-0306-x CrossRefPubMed

70.

Lavigne KM, Rapin LA, Metzak PD, Whitman JC, Jung K, Dohen M, Loevenbruck H, Woodward TS (2015) Left-dominant temporal-frontal hypercoupling in schizophrenia patients with hallucinations during speech perception. Schizophr Bull 41(1):259–267. https://doi.org/10.1093/schbul/sbu004 CrossRefPubMed

71.

Leroux E, Delcroix N, Dollfus S (2014) Left fronto-temporal dysconnectivity within the language network in schizophrenia: an fMRI and DTI study. Psychiatry Res 223(3):261–267. https://doi.org/10.1016/j.pscychresns.2014.06.002 CrossRefPubMed

72.

Palm U, Keeser D, Hasan A, Kupka MJ, Blautzik J, Sarubin N, Kaymakanova F, Unger I, Falkai P, Meindl T, Ertl-Wagner B, Padberg F (2016) Prefrontal transcranial direct current stimulation for treatment of schizophrenia with predominant negative symptoms: a double-blind, sham-controlled proof-of-concept study. Schizophr Bull 42(5):1253–1261. https://doi.org/10.1093/schbul/sbw041 CrossRefPubMedPubMedCentral

73.

Shi C, Yu X, Cheung EF, Shum DH, Chan RC (2014) Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis. Psychiatry Res 215(3):505–513. https://doi.org/10.1016/j.psychres.2013.12.019 CrossRefPubMed

74.

Dlabac-de Lange JJ, Knegtering R, Aleman A (2010) Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis. J Clin Psychiatry 71(4):411–418. https://doi.org/10.4088/JCP.08r04808yel CrossRefPubMed

75.

Freitas C, Fregni F, Pascual-Leone A (2009) Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophr Res 108(1–3):11–24. https://doi.org/10.1016/j.schres.2008.11.027 CrossRefPubMedPubMedCentral

76.

Wobrock T, Guse B, Cordes J, Wolwer W, Winterer G, Gaebel W, Langguth B, Landgrebe M, Eichhammer P, Frank E, Hajak G, Ohmann C, Verde PE, Rietschel M, Ahmed R, Honer WG, Malchow B, Schneider-Axmann T, Falkai P, Hasan A (2015) Left prefrontal high-frequency repetitive transcranial magnetic stimulation for the treatment of schizophrenia with predominant negative symptoms: a sham-controlled, randomized multicenter trial. Biol Psychiatry 77(11):979–988. https://doi.org/10.1016/j.biopsych.2014.10.009 CrossRefPubMed

77.

Plaze M, Paillere-Martinot ML, Penttila J, Januel D, de Beaurepaire R, Bellivier F, Andoh J, Galinowski A, Gallarda T, Artiges E, Olie JP, Mangin JF, Martinot JL, Cachia A (2011) “Where do auditory hallucinations come from?”—a brain morphometry study of schizophrenia patients with inner or outer space hallucinations. Schizophr Bull 37(1):212–221. https://doi.org/10.1093/schbul/sbp081 CrossRefPubMed

78.

Barry SJ, Gaughan TM, Hunter R (2012) Schizophrenia. BMJ Clin Evid 2012:1007PubMedPubMedCentral

79.

Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154(4):457–465. https://doi.org/10.1176/ajp.154.4.457 CrossRefPubMed

80.

Savill M, Banks C, Khanom H, Priebe S (2015) Do negative symptoms of schizophrenia change over time? A meta-analysis of longitudinal data. Psychol Med 45(8):1613–1627. https://doi.org/10.1017/S0033291714002712 CrossRefPubMed

81.

Sun D, Stuart GW, Jenkinson M, Wood SJ, McGorry PD, Velakoulis D, van Erp TG, Thompson PM, Toga AW, Smith DJ, Cannon TD, Pantelis C (2009) Brain surface contraction mapped in first-episode schizophrenia: a longitudinal magnetic resonance imaging study. Mol Psychiatry 14(10):976–986. https://doi.org/10.1038/mp.2008.34 CrossRefPubMed

82.

Kasai K, Shenton ME, Salisbury DF, Hirayasu Y, Onitsuka T, Spencer MH, Yurgelun-Todd DA, Kikinis R, Jolesz FA, McCarley RW (2003) Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 60(8):766–775. https://doi.org/10.1001/archpsyc.60.8.766 CrossRefPubMedPubMedCentral

Title: Neural substrate of unrelenting negative symptoms in schizophrenia: a longitudinal resting-state fMRI study
Authors: Mingli Li
Wei Deng
Tushar Das
Yinfei Li
Liansheng Zhao
Xiaohong Ma
Yingcheng Wang
Hua Yu
Xiaojing Li
Ya-jing Meng
Qiang Wang
Lena Palaniyappan
Tao Li
Publication date: 01-10-2018
Publisher: Springer Berlin Heidelberg
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 7/2018
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-017-0851-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Neural substrate of unrelenting negative symptoms in schizophrenia: a longitudinal resting-state fMRI study

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2018

Possibly no baseline severity effect for antidepressants versus placebo but for antipsychotics. Why?

Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis

Cannabinoids and glial cells: possible mechanism to understand schizophrenia

Olfactory deficits in individuals at risk for psychosis and patients with schizophrenia: relationship with socio-cognitive functions and symptom severity

Self-disorders in schizophrenia-spectrum disorders: a 5-year follow-up study

Is electroconvulsive therapy an evidence-based treatment for catatonia? A systematic review and meta-analysis